DLL4
DLL4 Informations sur la molécule
| Nom anglais | Delta-like protein 4 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 3 | Alias de la cible | Delta-Like Protein 4，Notch Ligand Delta-2，DLL4，Delta4，Delta-Like 4 (Drosophila)，Delta-Like 4 Homolog (Drosophila)，AOS6，Hdelta2，Notch Ligand DLL4，Delta Like Canonical Notch Ligand 4，Delta 4，Delta Ligand 4，Delta-Like 4 Protein，Drosophila Delta Homolog 4，Delta-Like 4 Homolog |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Delta-like protein 4 |
| Alias de la cible | Delta-Like Protein 4，Notch Ligand Delta-2，DLL4，Delta4，Delta-Like 4 (Drosophila)，Delta-Like 4 Homolog (Drosophila)，AOS6，Hdelta2，Notch Ligand DLL4，Delta Like Canonical Notch Ligand 4，Delta 4，Delta Ligand 4，Delta-Like 4 Protein，Drosophila Delta Homolog 4，Delta-Like 4 Homolog |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 3 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
DLL4 Liste de produits
- Attribut
Protein (10)Cell Grade Beads (4)Kits (2)
- Bibliothèque de produits
En ligne (16)
- Espèces
Human (13)- (3)
- Étiquette
Fc Tag (6)His Tag (1)His Tag & Avi Tag (2)- (6)Fc Tag & Avi Tag (1)
- Marqueur
Unconjugated (7)Biotin-labeled (3)- (6)
Ajouter au panier
Quantité totale16
- 1
- 2
DLL4Contexte de la molécule
Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.
DLL4Alias de la molécule
DLL4,Delta4
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Tovecimig | ES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001 | Phase 3 Clinical | Abl Bio Inc | Ampullary Carcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Rectal Neoplasms; Solid tumours | Details |
| Navicixizumab | OMP-305B83 | Phase 3 Clinical | Oncomed Pharmaceuticals Inc | Colorectal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Neoplasms; Solid tumours | Details |
Avis sur les produits
A***r2025-11-15
0Mettre un likeI have been using ACRO Biosystems products since 2021, especially DLL4 Fc proteins (DL4-H5259), refer to our published article: https://pubmed.ncbi.nlm.nih.gov/37795096/, where we have used Acro-products and obtained excellent results. I am very satisfied with the consistent quality and reliability of ACRO’s products. Thanks, Ankit Tanwar Staff Scientist AECOM, NY- Z***a2022-07-06 1Mettre un likeThis product was extremely useful for our T cell work. The vial it came in was easy to use (sometimes you'd be surprised how obtuse the packaging of a compound can be by certain companies) and has not lead to any issues with our research in many months. The only obstacle we have ever faced with adherent cells was as a result of our flat bottom plates being too old (and thus the coating wore off). So this product was more stable and consistent than the plates we put them on!
- Informations sur la molécule
- Liste de produits
- Avis sur les produits
- Informations sur les médicaments cliniques